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Background: Valid registration of medical information is essential for the quality of registry-based research.
Hyperemesis gravidarum (HG) is characterized by severe nausea and vomiting, weight loss and electrolyte
imbalance starting before 22nd gestational week. Given the fact that HG is a generally understudied disease
which might have short- and long- term health consequences for mother and child, it is of importance to know
whether potential misclassification bias influences the results of future studies. We therefore assessed the validity
of the HG-registration in the in Medical Birth Registry of Norway (MBRN) using hospital records.
Methods: The sample comprised all women registered in MBRN with HG and who delivered at Ullevål and
Akershus hospitals in 1.1.-31.3.1970, 1.4.-30.6.1986, 1.7.-30.9.1997 and 1.10.-31.12.2001. A random sample of 10
women per HG case, without HG according to MBRN, but who delivered during the same time periods at the
same hospitals was also collected. The final sample included 551 women. Sensitivity, specificity, positive and
negative predictive values (PPV and NPV) were estimated using strict and less strict diagnostic criteria of HG,
indicating severe and mild HG, respectively. Hospital journals were used as gold standard.
Results: Using less strict diagnostic criteria of HG, sensitivity, specificity, PPV and NPV were 83.9% (95% CI: 67.4-92.9),
96.0% (95% CI: 93.9-97.3), 55.3% (95% CI: 41.2-68.6) and 99.0% (95% CI: 97.7-99.6), respectively. For strict diagnostic
criteria, being hospitalised due to HG the corresponding values were 64% (95% CI: 38.8-87.2), 92% (95% CI:
90.2-94.6), 18.6% (95% CI: 10.2-31.9) and 99.0% (95% CI: 97.7-99.6).
Conclusions: The results from our study are comparable to previous research on disease registration in MBRN,
and show that MBRN can be considered valid for mild HG but not for severe HG.
Keywords: Hyperemesis gravidarum, Validity study, Medical Birth Registry of NorwayBackground
During the late 1950s and early 1960s Thalidomide was
prescribed to women suffering from nausea and vomit-
ing in early pregnancy, resulting in more than 10 000
limb deformities globally [1,2]. The Medical Birth Regis-
try of Norway (MBRN) was established in 1967 reflect-
ing the need for epidemiological surveillance of birth
defects [3]. Since then, MBRN has become a unique
source of perinatal data comprising several generations.
Additionally, MBRN contains valuable information on
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reproduction in any medium, provided the orand after pregnancy, although incomplete ascertainment
has been and still is a concern [4].
Valid registration of medical information is essential
for the quality of registry-based research. Previous stu-
dies validating disease registration of in MBRN have
shown diverging results, depending on the condition
[4-8]. Engeland evaluated the validity of diabetes type 1
among 1.929 million women registered in MBRN using the
Norwegian Prescription Database and found a sensitivity of
90% and specificity of 100% [5]. For any type of diabetes
the corresponding values were 72% and 99%, although for
asthma the sensitivity was 51% and specificity 98%. Smaller
studies using hospital records as gold standard have
reported the sensitivity for maternal rheumatic disease in
MBRN to be 88% and for myasthenia gravis 99% [4,6]. Spe-
cificities were not reported. The obstetric sphincter tearsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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using Patient Administrative Systems finding a sensitivity
of 91.8% and specificity of 91.8% [7]. Another study explor-
ing the validity of unexplained foetal deaths among 10.857
singleton pregnancies in MBRN using hospital records and
results from autopsies, reported a sensitivity of 78% and
specificity of 88% [8].
Hyperemesis gravidarum (HG) is characterised by
severe nausea and vomiting starting before the 22nd
gestational week, often leading to weight loss and nutri-
tional deficiencies [9,10]. The validity of the HG registra-
tion in MBRN has not yet been investigated, although
previous studies using the data from MBRN have found
the prevalence of HG to be similar to the prevalence
observed in neighbouring countries [11-13]. Whereas up
to 90% of all pregnant women report nausea or nausea
and vomiting (NVP), HG affects 0.3-3.2% [9,13]. Earlier
research has been influenced by the fact that HG and
the more common NVP have been studied as one and
the same condition; but so far we do not know if or how
these two conditions are related [14-18].
Additionally HG is a generally understudied disease,
which might have short and long term health conse-
quences for mother and child, such as increased risk of
rheumatic disease among mothers and increased risk of
testicular cancer and leukaemia among children [19-22].
Although MBRN in an international context provides an
extremely large dataset, it is important to know whether
potential systematic errors influence the results of previ-
ous and future studies using MBRN. Our aim was there-
fore to investigate the validity of the HG registration in
MBRN using hospital records as gold standard.
Methods
Notification to MBRN is compulsory and is provided by
midwives and physicians attending the birth using a
standardised form [3]. From 1967 to 1998 pregnancy
outcomes were notified from the 16th gestational week,
after 1998 from the 12th gestational week. Maternal dis-
eases before and during pregnancy are also notified.
Women with HG in MBRN were registered according to
International Classification of Diagnoses (ICD) [10]. From
1967 to 1998 HG was registered by the ICD-8 codes 638.0
(hyperemesis gravidarum with neuritis), 638.9 (hypere-
mesis gravidarum without mention of neuritis), and 784. 1
(nausea and vomiting) [11]. From 1999 and onwards HG
was registered by the ICD-10 codes O21.0 (mild hyperem-
esis gravidarum), O21.1 (hyperemesis gravidarum with
metabolic disturbances), and O21.9 (vomiting in preg-
nancy, unspecified) [13].
The sample consisted of all women registered with
HG in MBRN who delivered their babies at Ullevåla
and Akershusb hospitals during four time periods: 1.1-
31.3.1970, 1.4-30.6.1986, 1.7-30.9.1997 and 1.10-31.12.2001.The sample also included a random selection of women
not registered with HG in MBRN, but who delivered
during the same time periods at the same hospitals; ten
women were selected per HG case.
Altogether 599 women delivering in Ullevål and
Akershus hospitals during the four time periods were
selected for the study. Among them, 53 women were
registered with HG in MBRN. Informed consent in
accordance with guidelines of the Ministry for Health
and Care Services was obtained from all women included
in the study sample. Altogether, 19 women did not give
their consent and were excluded. Furthermore, 29 hos-
pital records were missing resulting in exclusion of these
women. Our final study sample therefore comprised
551women among whom 48 women were registered with
HG in MBRN and 503 women were not (Figure 1).
The hospital record was considered as gold standard
and checked manually. In order to validate the HG
registration in MBRN we investigated all information
within the women’s hospital records including patient
journals, laboratory sheets with test results from blood
and urine samples and antenatal cards. An antenatal
card is a standardised form all pregnant women in
Norway receive at their first routine examination early
during the first trimester in pregnancy. The antenatal
card is later used as medical record for midwifes and
medical doctors during the entire pregnancy. After birth
the antenatal card is filed within the hospital record and
provides information from all examinations in preg-
nancy, such as the mother’s height, weight, blood pres-
sure, urine samples, the need of sick leave etc. The
antenatal card also provides information on any specific
symptom or complaint the pregnant woman might have,
such as HG.
In order to be registered with HG based on strict diag-
nostic criteria, indicating severe HG, the women had to
have been admitted to hospital due to HG. In addition
two out of the three following symptoms had to be
reported in the hospital record; weight loss, dehydration
or ketonuria. If the woman had been admitted to hos-
pital because of HG during the actual pregnancy, her
patient journal or laboratory sheets provided data on
symptoms such as nausea and vomiting, weight loss,
dehydration and ketonuria.
In order to be registered with HG based on less strict
diagnostic criteria, indicating mild HG, the women did
not have to have been admitted to hospital due to HG.
If she was not admitted to hospital because of HG, her
antenatal card, which is filed within the hospital record,
contains the necessary health information. Since most
women experience some degree of nausea and vomiting
during pregnancy (NVP) we considered that the nausea
and vomiting worth describing on her antenatal card or
was mentioned in her patient journal would be more
53 women were registered in the Medical Birth Registry of Norway (MBRN) with  
hyperemesis gravidarum (HG)
546 women not registered with HG in MBRN - randomly selected  
(N=599)
19 women - no consent 
29 women    no hospital records 
(N=48)
Final sample
48 women registered with HG in MBRN  
503 not registered with HG in MBRN  
(N=551)
Source population
Women delivering at Ullevål and Akershus University hospitals in
selected time periods from 1970 to 2001
Figure 1 Sampling frame.
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tered as mild hyperemesis [14]. One hospital record was
missing when less strict diagnostic criteria were applied.
Sensitivity, specificity, positive (PPV) and negative
(NPV) predictive values were calculated using hospital
records as gold standard. Wilson’s method was used to
calculate with 95% confidence intervals (CI) for the esti-
mates. All calculations were performed using Confidence
Intervals Analysis software.
This study was approved by the Data Inspectorate,
the Ministry for Health and Care Services and the
Norwegian Scientific-Ethical Committees.
Results
Sixty-nine percent of the hyperemesis patients were
registered by ICD 8 (1967–1998) and 31% by ICD 10
(1999–2006). Among the 48 women with HG in MBRN,
31 women were registered by the ICD 8 code 638.9, 2
women were registered by the ICD 8 code 784.1 and 15
women were registered by the ICD 10 code O21.9.The results of validating the HG registration in MBRN
using hospital records are shown in Table 1 and Table 2.
Table 1 reflects the validity of the HG diagnosis
in MBRN by the use of strict diagnostic criteria indicat-
ing severe HG. Among the 48 women registered with
HG in MBRN, 9 women were hospitalised due to severe
HG. According to all hospital records, 14 women were
hospitalised due to severe HG, indicating that 5 were
not registered with HG in MBRN. The use of strict diag-
nostic criteria resulted in a sensitivity of 64.3% (95% CI:
38.8-83.7), specificity of 92.7% (90.2-94.6), PPV of 18.6%
(10.2-31.9) and NPV of 99% (97.7-99.6).
Table 2 presents the corresponding results applying
less strict diagnostic criteria indicating mild HG. Among
the 48 women registered with HG in MBRN, 26 had the
disease according to the hospital records (Table 2). The
use of less strict diagnostic criteria resulted in a sensitiv-
ity of 83.9% (95% CI: 67.4-92.9), specificity of 96.0%
(93.9-97.3), PPV of 55.3% (41.2-68.6) and NPV of 99.0%
(97.7-99.6).
Table 1 Validity of HG registration in MBRN using






HG + in MBRN 9 39 48
HG – in MBRN 5 498 503
Total 14 537 551
Sensitivity (9/14) 64.3% 95% CI: 38.8-83.7
Specificity (498/537) 92.7% 95% CI: 90.2-94.6
Positive predictive
value (9/48)
18.6% 95% CI: 10.2-31.9
Negative predictive
value (498/503)
99.0% 95% CI: 97.7-99.6
1 Strict diagnostic criteria indicate severe HG.
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This is the first study to validate the registration of HG
in MBRN. When less strict diagnostic criteria, indicating
mild HG, were applied, the sensitivity was 83.9%, specifi-
city of 96.0%, PPV of 55.3% and NPV of 95.9%. These
results are comparable to previous research on disease
registration in MBRN, such as diabetes 1, showing that
HG is likewise valid for use in large epidemiologic stud-
ies when it comes to the mild form of the disease [4-6].
For strict diagnostic criteria, indicating severe HG, the
corresponding figures were 64.3%, 92.7%, 18.6% and
99.0%. The low PPV shows that MBRN is not valid for
severe HG. Thirty five percent of the women were ad-
mitted to hospital due to HG when less strict diagnostic
criteria were used, compared to 100% when strict criteria
were used. PPV reflects the probability of having HG in
accordance with the hospital record when registered
with HG in MBRN, and is depending on the prevalence
[13]. Since the registration of rare diseases is influenced
by false positive cases, the PPV is expected to be low
when the prevalence is low [23].Table 2 Validity of HG registration in MBRN using







HG + in MBRN 26 21 47
HG – in MBRN 5 498 503
Total 31 519 550
Sensitivity (26/31) 83.9% 95% CI: 67.4-92.9
Specificity (498/519) 96.0% 95% CI: 93.9-97.3
Positive predictive
value (26/47)
55.3% 95% CI: 41.2-68.6
Negative predictive
value (498/503)
99.0% 95% CI: 97.7-99.6
1 Less strict diagnostic criteria indicate mild HG.
2 One medical record went missing during the investigating period.A major strength of this study is the sample represent-
ing all HG patients registered in MBRN among women
who delivered during four different time periods from
1970 to 2001 in two large hospitals; hospitals now serv-
ing 19% of all births in Norway (unpublished data from
MBRN). Although the two hospitals selected might not
be representative for all Norwegian hospitals, selection
bias is not very likely due to the national guidelines
for diagnosing and treating HG worked out by the
Norwegian Society for Gynecology and Obstetrics [24].
Furthermore, hospital records are commonly used as
“gold standard” when registry data are being validated
[4,6,8,25]. A limitation of our study might be the low
number of women included.
Errors in information on HG in MBRN might have
occurred on three different levels; 1) by the midwife
or general practitioner filling in the antenatal card or
patient journal, 2) by the midwife or physician attending
the birth notifying MBRN, and 3) the registration at
MBRN. Even though diagnosing and treating HG in
Norway is carried out in accordance with national guide-
lines worked out by the Norwegian Society for
Gynecology and Obstetrics, there is always a chance for
misdiagnosing due to inexact diagnostic criteria in clin-
ical practice [26]. For women who had not been hospita-
lized due to HG, the midwife or physician notifying
MBRN had to rely on the information written on the
woman’s antenatal card. Although the ICD 8 as well as
ICD 10 codes allow differentiating between mild and
severe HG, HG is not registered as such in MBRN. In
our study MBRN mainly registered HG as 638.9 in ICD
8 and only as O21.9 in ICD 10. Due to the exclusive use
of O21.9, describing unspecific vomiting in pregnancy,
Kari Klungsøyr who is responsible for their coding pro-
cedures in MBRN, was contacted. She confirmed that
there might be a potential for misclassification bias
during the first period after ICD 10 was introduced (per-
sonal communication). Exclusion of O21.9 from the ana-
lysis would have resulted in losing a third of the sample,
which is why we present our data without excluding
those coded as such.
In order to be able to differentiate between mild and
severe HG we therefore decided to distinguish between
strict and less strict diagnostic criteria, indicating severe
and mild HG. The use of the different diagnostic criteria
showed that the majority of women registered with HG
in MBRN suffered from milder forms and was not hos-
pitalised due to HG. Also the fact that the ICD 8 code
784.1 was included in our study as HG represents a
source of error. This is due to the fact that ICD code
784.1 is not related to nausea and vomiting during preg-
nancy in particular. The reason for including this ICD
code in our study, was to be comparable with a previous
publication on HG using data from MBRN [11]. When
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for HG in MBRN increased from 55.3% to 57.8%.
Previous studies validating disease registration in
MBRN using hospital records as gold standard did only
report sensitivities and can therefore only partly be
compared to ours [4,6]. The sensitivity for HG is, how-
ever, comparable to the one for rheumatic disease as
well as myasthenia gravis [4,6]. Another study used the
Norwegian Prescription Database validating the registra-
tion of diabetes 1, all types of diabetes, epilepsy and
asthma in MBRN [5]. The validity for diabetes 1 in
MBRN was in line with our findings for mild HG with a
PPV of 56%. The validity for the registration of all types
of diabetes, epilepsy and asthma in MBRN was reflected
in lower sensitivities, specificities, PPV and NVP than
for mild HG. PPV for epilepsy and asthma was 37% and
46%, respectively.
A Swedish study on HG’s effect on pregnancy out-
comes suggested that the exposure-outcome associations
were diluted due to the probability of registering milder
forms of HG since the HG diagnosis not being well
defined [27]. Our study shows that this “dilution” is the
case for MBRN since MBRN is valid for mild HG. When
it comes to differentiating between mild HG and the
more common NVP, our sample did not provide the
opportunity to investigate this. For future studies it will
be important to be able to differentiate between the
more common nausea and vomiting in pregnancy, mild
HG and severe HG necessitating hospitalisation. Severe
forms of HG in particular are found to be associated
with adverse pregnancy outcomes, such as preterm birth
and low birth weight [28-30]. Severe HG and excessive
vomiting in pregnancy has also been reported as risk fac-
tors for the development of childhood leukaemia and
testicular cancer as well as rheumatic disease among
mothers [20,22,31]. In utero exposure to HG has also
been linked to a 3.6-fold risk of psychological and behav-
ioural disorders in the offspring [32].Conclusions
The results from our validity study show that MBRN
may be valid for mild HG, but not for severe HG. Fur-
thermore, the results are comparable to previous re-
search on disease registration in MBRN [4-6]. For future
studies on HG, MBRN is valid as database, although the
relatively large proportion of false positive cases might
influence the exposure-outcome associations in terms of
reducing associations closer to the null value.Endnotes
aOslo University Hospital Ullevål Hospital since 2009
bAkershus University Hospital since 2008Abbreviations
HG: Hyperemesis gravidarum; ICD: International Classification of Diseases;
MBRN: Medical Birth Registry of Norway; NPV: Negative predictive value;
NVP: Nausea and vomiting in pregnancy; PPV: Positive predictive value.
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